Achieve Life Sciences Inc. Company Profile
NASDAQ: ACHVHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
Market open · Delayed 15 min · as of Oct 8, 2:47 PM ET
Achieve Life Sciences at a glance
Achieve Life Sciences Inc. (NASDAQ: ACHV) is a Biotechnology: In Vitro & In Vivo Diagnostic Substances company in the Health Care sector headquartered in Bothell, WA. Achieve Life Sciences is led by Dr. Andrew D. Goldberg M.D. and employs about 28 people. At a market capitalization of $746.5 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0000949858, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Achieve Life Sciences do?
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Business description based on the company's public filings.
Company information
- Legal name
- Achieve Life Sciences Inc.
- Ticker
- NASDAQ: ACHV
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Dr. Andrew D. Goldberg M.D.
- Employees
- 28
- Headquarters
- 22722 29th Dr. SE, Bothell, WA, United States
- Phone
- 604 210 2217
- Website
- achievelifesciences.com
- Market cap
- $746.46M
- SEC CIK
- 0000949858
Companies similar to Achieve Life Sciences
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| QDELQuidelOrtho Corporation | 12.32 | +0.08% | $844.85M | vs ACHV |
| TKNOAlpha Teknova Inc. | 8.56 | -1.72% | $459.57M | vs ACHV |
| MYGNMyriad Genetics Inc. | 4.21 | -1.75% | $402.21M | vs ACHV |
| NNNNAnbio Biotechnology Class A | 4.56 | -6.94% | $200.14M | vs ACHV |
| IMDXInsight Molecular Diagnostics Inc. | 3.25 | -6.07% | $106.35M | vs ACHV |
| ICCCImmuCell Corporation | 9.75 | +0.62% | $88.55M | vs ACHV |
| BMRABiomerica Inc. | 1.87 | -1.58% | $8.60M | vs ACHV |
| VNRXVolitionRX Limited | 0.2213 | -2.08% | $6.65M | vs ACHV |